Rhinovirus diagnostics market seen reaching $2.33 billion by 2030

The rhinovirus diagnostics market is projected to grow from $1.58 billion in 2025 to $2.33 billion by 2030, driven by demand for faster respiratory testing, multiplex panels and AI tools. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Rhinovirus diagnostics help clinicians identify a common cause of respiratory illness faster, which can improve treatment decisions and help limit spread. - The market’s growth reflects broader demand for more accurate respiratory infection testing as respiratory disorders rise worldwide.

What happened: - The Business Research Company released a report on the rhinovirus diagnostics market covering 2026-2035. - The market was estimated at $1.58 billion in 2025 and is forecast to reach $1.71 billion in 2026. - The report projects the market will climb to $2.33 billion by 2030, implying an 8.2% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - Download a free sample of the report - View the full market report

The details: - Historical growth was tied to rising common cold and respiratory infection cases, wider use of molecular diagnostics, better hospital lab testing, limits of traditional virus culture and greater awareness of early diagnosis. - Future growth is expected to be driven by rapid point-of-care tests, AI-assisted interpretation, multiplex panels for multiple respiratory pathogens, higher investment in infectious disease monitoring and precision medicine approaches. - Key trends include AI-enhanced pathogen identification, broader multiplex PCR respiratory virus panels, more point-of-care rhinovirus devices, cloud-based surveillance platforms and more sensitive molecular assays. - Rhinovirus diagnostics use laboratory and clinical tests to detect and confirm rhinovirus infections, usually from respiratory samples. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated technology and trend analysis.

Between the lines: - The forecast suggests rhinovirus testing is moving beyond basic detection toward faster, more automated and more integrated respiratory diagnostics. - Rising healthcare spending is also supporting market expansion by making advanced diagnostics and testing infrastructure more accessible. - The report cites a UK Office for National Statistics update showing healthcare spending in 2024 reached about $29.88 billion (£317 billion), up 6.5% from 2023. - The report also cites National Center for Biotechnology Information projections that COPD cases could rise by 112 million to 592 million by 2050, equal to 9.5% of the eligible population.

What's next: - The market is expected to keep expanding as hospitals and labs adopt faster respiratory testing tools and multiplex systems. - Growth in cloud-based surveillance and AI-supported diagnostics could reshape how rhinovirus and other respiratory infections are tracked and identified. - The Business Research Company says its broader research library includes more than 30,000 reports across 27 industries and 60 geographies.